Atyr Pharma Inc. (NASDAQ:LIFE) was down 2.5% during mid-day trading on Thursday . The company traded as low as $2.71 and last traded at $2.74, with a volume of 184,785 shares traded. The stock had previously closed at $2.81.

A number of equities research analysts recently issued reports on LIFE shares. William Blair downgraded Atyr Pharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 31st. BMO Capital Markets started coverage on Atyr Pharma in a research report on Monday, April 11th. They issued a “market perform” rating on the stock. Finally, Zacks Investment Research downgraded Atyr Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $23.75.

The firm’s 50 day moving average price is $3.03 and its 200-day moving average price is $4.59. The stock’s market cap is $67.51 million.

Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, May 11th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.02. Analysts forecast that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In other Atyr Pharma news, Director Paul Schimmel acquired 9,127 shares of the business’s stock in a transaction dated Tuesday, April 12th. The stock was purchased at an average price of $3.71 per share, with a total value of $33,861.17. Following the transaction, the director now directly owns 20,412 shares in the company, valued at approximately $75,728.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Grove Matsuoka acquired 12,412 shares of the business’s stock in a transaction dated Wednesday, May 11th. The shares were acquired at an average cost of $3.04 per share, with a total value of $37,732.48. Following the transaction, the insider now owns 2,412 shares in the company, valued at $7,332.48. The disclosure for this purchase can be found here.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.